Evidence map›Paper›PMID 41256140›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.

Venise Jan Castillon, Amy X Xie, Sonia Boscenco, Ethan Tse, Neil Ruthen, Jamie Wang, Ziad El Bakouny, Michele Waters, Chenlian Fu, Christopher Fong and 7 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Venise Jan CastillonComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Amy X XieComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Sonia BoscencoComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Ethan TseComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Neil RuthenComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Jamie WangComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Ziad El BakounyComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Michele WatersComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Chenlian FuComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Christopher FongComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Urvi A ShahDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-8419-1091
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0930-8824
Justin JeeComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9783-0139
Eileen WhiteRutgers Cancer Institute, Rutgers University, New Brunswick, NJ.ORCID 0000-0003-2961-3065
Tobias JanowitzCold Spring Harbor Laboratory, Cold Spring Harbor, NY.ORCID 0000-0002-7820-3727
Marcus D GoncalvesHolman Division of Endocrinology, Diabetes & Metabolism, Department of Medicine and Radiation Oncology, NYU Langone Health, New York, NY.ORCID 0000-0002-0784-9248
Ed ReznikComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6511-5947

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
CANCAN-RUTGERSOT2CA278609 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Eileen P. White · 2022 to 2026
$2.6M
Defining the function of Complex I truncating mutations in cancerR37CA276200 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Payam Gammage, Eduard Reznik · 2023 to 2026
$2.5M
NCI NIH HHS OT2 CA278609NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA276200
6 · The paper itself

Abstract

Cancer cachexia is a wasting syndrome with outsized impact on morbidity and mortality. Neither the etiology of cachexia, nor its consequences on patient physiology and outcomes, are well-understood. Here, we repurposed longitudinal clinicogenomic data from 59,493 cancer patients to define episode-resolved trajectories of cachexia and linked them to serology, tumor genotypes, and clinical outcomes. Cachexia risk concentrated around periods of disease progression and associated with inferior outcomes in nearly all cancer types. Across cancers, cachectic episodes exhibited a consistent serologic signature characterized by low albumin and hemoglobin and high levels of liver enzymes. Numerous somatic tumor genotypes, including

Identifiers

PMID41256140
PMCPMC12622151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.